key: cord-1030007-1ra9bosz
authors: Marsland, Laura; Fang, Cheng; Garzillo, Giorgio; Batohi, Bhavna; Teo, James T.H.; Berovic, Marko; Waller, Michael D.; Sidhu, Paul S.; Robbie, Hasti
title: Re: Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease
date: 2020-10-08
journal: Clin Radiol
DOI: 10.1016/j.crad.2020.09.019
sha: 5bdaa24705247c6fe5df0c69ac9390db92cee646
doc_id: 1030007
cord_uid: 1ra9bosz

nan

relationship with pulmonary parenchymal disease Sir-We recently reported an overall incidence of pulmonary thromboembolism (PTE) of 44% in hospitalised patients with COVID-19 (1) . It has been observed that for a significant number of patients, the symptoms of respiratory dysfunction persist beyond the acute phase of the disease (2) . The aim of this letter is to report the incidence of PTE in hospitalised patients with severe COVID-19 who have persistent respiratory illness well after their initial presentation. This follow-up project has the same ethics approval as the original study.

We retrospectively reviewed hospitalised COVID-19 patients from our initial cohort (1) who attended a specialist respiratory follow-up clinic 3-6 months after discharge and met the criteria for follow-up clinical assessment (Fig. 1) . From the 1,200 patients admitted to our hospital between 23 March to 19 April 2020, 201 patients met the criteria for a follow-up review (Fig. 1) . A medical assessment including a standardised symptom questionnaire and 1-minute sit-to-stand exercise desaturation test was performed in order to determine the requirement for further CT imaging ( J o u r n a l P r e -p r o o f One hundred and sixty-six patients attended, including 106 men (64%), with a median age of 57 years (range 25-84 years). Thirty-five patients did not attend.

Eighty-nine of the 166 (53.6%) patients (median age: 56 years, range 25-84 years) met the criteria for CT chest imaging (Table 1) One patient out of the 49 patients not previously diagnosed with PTE was diagnosed with new-onset lobar PTE during the follow-up. The remaining 48 patients had negative CTPA during follow-up; 12/48 (25%) of these patients were referred for SPECT imaging due to high clinical suspicion for PTE. Two of the 12 showed peripheral perfusion defects suggestive of distal PTE and were subsequently treated with anticoagulation therapy. Therefore, the overall incidence of PTE in our cohort of patients who attended follow-up clinic without previously known PTE was 6.1% This observational study confirms that in patients recovering from severe COVID-19 who remain symptomatic on follow-up, the incidence of new PTE was significantly lower at 6.1% compared to 44% reported by this group during the acute phase of the disease. Persistent signs and symptoms of respiratory dysfunction in patients recovering from severe COVID-19 pneumonia are therefore unlikely to be due to PTE, but more likely as a result of persistent lung parenchymal disease with ≥50% Indication for CT of the thorax ± CTPA

• Increased dyspnoea since hospital discharge OR • Desaturation ≥4% on exercise or persisting dyspnoea resulting in reduced exercise tolerance level compared to pre-COVID level OR • Persisting chest radiography abnormalities at 6 weeks (greater than 1/3 lung involvement) OR • Chest radiography appearances suggestive of fibrotic lung damage OR • Less than 50% improvement in chest radiography abnormalities at 6 weeks OR • Patients already on anticoagulation therapy for PTE during initial hospital admission showing worsening of symptoms warrant repeated imaging to exclude worsening of clot burden Indication for CT thorax only (for those who met the above criteria, but CTPA is not required for the following reasons)

• Already on anticoagulation therapy with symptoms suggesting persistent parenchymal disease • Symptoms predominately suggest parenchymal disease rather than PTE • Contraindication to intravenous iodine contrast medium CT computed tomography; CTPA, CT pulmonary angiography; PTE, pulmonary thromboembolism.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease

for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19

Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic